INTRODUCTION
Oral human papillomavirus (HPV) infection has a prevalence of approximately 6.9% in the US population, with the Centers for Disease Control and Prevention estimating the prevalence of high-risk subtypes in particular at 6.8% among men and 1.2% among women aged 18 to 69 years. 1, 2 Human papillomavirus-associated (HPV1) oropharyngeal cancer, 1 of the primary subtypes of oropharyngeal carcinoma based on causative agent, has been rapidly increasing in incidence since the early 1970s. It currently comprises approximately two-thirds of oropharyngeal cancers, and represents the most common HPV-associated cancer in the United States. [3] [4] [5] [6] [7] HPV1 cancers of the oropharynx have been shown to have a better prognosis than those that are negative for HPV (HPV-). 6, [8] [9] [10] [11] [12] [13] [14] On the basis of this improved prognosis, the recently released American Joint Committee on Cancer (AJCC) eighth edition staging criteria now account for HPV status when staging oropharyngeal cancers. However, national treatment guidelines do not differentiate therapy based on HPV status, indicating that it should only be used as a prognostic indicator. Current National Comprehensive Cancer Network (NCCN) guidelines use the AJCC seventh edition staging criteria and suggest definitive radiotherapy (RT) or primary surgery for patients with T1-T2/N0 or T1N1 disease and definitive chemoradiotherapy (CRT) or surgery with adjuvant therapy for patients whose disease is classified as T2N1, T3-T4/N0-N1, or N2-N3 with any T classification. 15 Recently, however, given the improved prognosis of patients with HPV1 cancers, de-escalation of treatment is being trialed to determine whether long-term toxicities can be decreased without impairing outcomes. [16] [17] [18] Researchers have identified lower risk subgroups within high-stage disease for which deintensified treatment may be safest based on overall survival and risk of distant metastases. 8, [19] [20] [21] Varied strategies have been proposed to de-escalate treatment in these patients. Currently under study are decreased radiotherapy dose (ClinicalTrials.gov identifiers NCT02945631, NCT02215265, and NCT01706939), decreased irradiated volume of the pharynx (ClinicalTrials.gov identifier NCT03224000), use of a chemoselection approach to minimize subsequent RT dose (ClinicalTrials.gov identifier NCT01084083), substitution of platinum regimens by targeted therapies (ClinicalTrials.gov identifiers NCT01663259, NCT01855451, NCT02298595, and NCT01302834), avoidance of surgical resection (ClinicalTrials.gov identifier NCT03210103), and avoidance of chemotherapy from definitive/adjuvant treatment (ClinicalTrials.gov identifier NCT02215265). 22 The last of these, removal of chemotherapy from the adjuvant or definitive treatment regimen, has been the topic of some debate in the literature and is the focus of the current study. 22, 23 This idea is fueled by publications that suggest that there might be increased acute/late toxicities and feeding tube dependence associated with cisplatin-based chemotherapy for patients with head and neck cancer. 24, 25 In one study of long-term dysphagia after definitive RT for head and neck cancer, receipt of concurrent chemotherapy was found to be the strongest predictor of long-term swallowing dysfunction, even compared with RT dose. 26 Another study of patients receiving intensity-modulated RT for oropharyngeal cancer found that the only independent predictors of mucositis were radiation volume and receipt of concomitant chemotherapy. 27 Current data regarding outcomes for patients receiving reduced modality treatment are limited, although a recent single-institution study in a group of patients with T1-T3/N1-2b and T3/N0 disease found that there was no compromise in progression-free survival between patients receiving RT alone versus concurrent CRT. 28 Conversely, a recent study by Roden et al found that treatment with triple-modality therapy is associated with improved outcomes compared with other treatment combinations for advanced stage tonsillar cancers, although they did not account for HPV status. 29 To our knowledge, the association of triple-modality therapy with improved outcomes has not been extensively explored in the literature.
The objective of the current study was to investigate the relationship between treatment modalities and survival for HPV1 oropharyngeal cancers for patients with AJCC eighth edition stage I, stage II, and stage III disease. The primary objective was to evaluate whether the proposed de-escalation strategy from CRT to RT alone in patients with stage I or stage II disease was associated with diminished survival. For patients with stage III disease, we aimed to explore whether triple-modality therapy was associated with improved survival compared with other treatment combinations. Finally, in the stage I and stage II groups, we aimed to explore whether there was any difference in survival based on the addition of adjuvant therapy to definitive surgery. To accomplish this, we examined a cohort of 4443 patients from the American College of Surgeons Commission on Cancer's National Cancer Data Base (NCDB) who were diagnosed between 2009 and 2013 inclusive. The results may provide insight into the types of HPV1 oropharyngeal cancer that are amenable to treatment with fewer modalities, and the treatment modalities that provide the safest options for deescalation.
MATERIALS AND METHODS

Data Source
Data originated from the NCDB from 2004 to 2016. The NCDB is a nationwide clinical surveillance resource data set that includes approximately 70% of all newly diagnosed malignancies in the United States from >1500 cancer programs as previously described. 30 This study was determined to be exempt from institutional review by the Yale Human Investigation Committee.
Study Population
Our selection criteria are presented in Figure 1 . We identified adult (those aged 18 years) patients with a primary tumor site in the oropharynx, squamous histology, and known HPV status. Oropharynx primary tumors were identified via the following International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes: C09.0 (tonsillar fossa; 460 cases), C09.1 (tonsillar pillar; 150 cases), C09.8 (overlapping lesion of tonsil; 65 cases), C09.9 (tonsil, not otherwise specified; 3421 cases), C10.0 (vallecula; 48 cases), C10.1 (anterior surface of epiglottis; 8 cases), C10.2 (lateral wall of oropharynx; 32 cases), C10.3 (posterior wall of oropharynx; 19 cases), C10.8 (overlapping lesion of oropharynx; 57 cases), and C10.9 (oropharynx, not otherwise specified; 183 cases). HPV positivity was determined by identified high-risk variant HPV DNA. Patients were excluded if they had other malignancies, were missing follow-up data, were missing clinical stage, received nontherapeutic doses of RT, or received combined treatment outside therapeutic time windows as described in the following section. We also excluded diagnosis years, for which there were <25 eligible patients.
Statistical Analysis
We used demographic, clinical, and outcomes variables in the analysis. Clinical AJCC eighth edition staging was determined based on conversion of seventh edition clinical staging. Comorbidity was measured by the Charlson/ Deyo Comorbidity Score, with 0 corresponding to no comorbidity; 1 to cardiovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, or diabetes; and 2 to diabetes with chronic complications, hemiplegia or paraplegia, renal disease, moderate or severe liver disease, or acquired immunodeficiency syndrome (AIDS). Patients were defined as having received surgery if they underwent surgical resection at the primary tumor site. Patients were defined as having received chemotherapy if they received any chemotherapy, regardless of the type or number of agents. Patients were considered as having received RT if they received beam radiation. Patients were included in the surgery-only group if they received surgery but no RT or chemotherapy; in the surgery plus RT group if they received surgery along with starting RT within 90 days after the date of their surgery, but no chemotherapy; in the surgery plus CRT group if they received surgery along with starting RT within 90 days after the date of their surgery and starting chemotherapy within 30 days of their first radiation treatment; in the CRT group if they started chemotherapy within 30 days of their first radiation treatment; and in the RT group if they received RT but no surgery or chemotherapy. Patients were determined to have received nontherapeutic doses of radiation if they received <60 grays (Gy) for definitive RT or <50 Gy for adjuvant RT.
We completed chi-square analyses to measure the association between patient disease stage and treatment combination stratified by disease stage. All variables then were included in Cox multivariate regressions stratified by disease stage. Next, we performed Kaplan-Meier analyses of survival stratified by treatment combination and disease stage. Treatment groups with <20 patients were excluded from Kaplan-Meier analysis due to high variance and low power. Statistical significance was determined at the P<.05 level. All data analysis was performed using STATA statistical software (version 13; StataCorp LP, College Station, Texas).
RESULTS
Population Characteristics
Among patients with known HPV status, slightly greater than two-thirds were HPV1 and were included in the current study. The remaining characteristics of the study population are described in Table 1 . The majority of patients were white (90.6%), male (84.6%), aged <65 years (81.1%), had no comorbidities (84.6%), and had positive lymph node status (84.7%). Kaplan-Meier survival by disease risk is presented in Figure 2 .
Stage I
There were 3198 patients in the stage I group. The most common treatment combinations were surgery with CRT (36.8%) and definitive CRT (29.7%) ( Table 1 ). Patient T classification was associated with the received treatment (Fig. 3A) . The addition of adjuvant CRT (HR, 0.558; 95% CI, 0.348-0.894) or adjuvant RT (HR, 0.528; 95% CI, 0.310-0.901) to definitive surgery was associated with improved outcomes. The 3-year survival rate was 80.6% (SE, 4.1) for patients treated with definitive RT and 91.2% (SE, 1.7), 91.3% (SE, 1.1), 94.7% (SE, 1.1), and 94.9% (SE, 0.8), respectively, for those treated with surgery alone, definitive CRT, surgery with adjuvant RT, and surgery with adjuvant CRT.
Stage II
Among the 795 patients with stage II disease, the most common treatment combinations were surgery with CRT (24.4%) and definitive CRT (62.3%) ( Table 1 ). Patient T classification was found to be associated with the received treatment combination (P 5 .002), with 58.7% of patients with T1 lesions treated with surgery with or without adjuvant therapy compared with 35.8% of patients with T2 lesions and 31.4% of patients with T3 lesions. Patient N classification was also found to be associated with treatment combination (P<.001), with 48.0% of patients with N0 tumors treated with surgery with or without adjuvant therapy compared with 31.1% of patients with N1 tumors and 32.6% of patients with N2 tumors. Neck dissection was performed in 67.6%, 60.0%, and 29.0%, respectively, of patients who received surgery alone, surgery with RT, and surgery with CRT. The median RT dose was lower for adjuvant RT (60.0 Gy) than adjuvant CRT (70.0 Gy) or definitive therapy (CRT: 70.0 Gy and RT: 70.0 Gy). The 3-year survival rate in the overall group was 82.7% (SE, 1.7).
Survival varied significantly by treatment combination (Table 2) . Treatment with either RT alone (HR, 2.200; 95% CI, 1.079-4.484) or surgery alone (HR, 2.539; 95% CI, 1.261-5.112) was found to be associated with reduced survival compared with receipt of definitive CRT. Survival curves also demonstrated reduced survival for these single-modality therapies (Fig. 3B ). The addition of adjuvant CRT to definitive surgery was associated with improved survival (HR, 0.510; 95% CI, 0.124-0.608) whereas the addition of adjuvant RT trended toward but failed to reach statistically significant improved survival (HR, 0.510; 95% CI, 0.180-1.441). The 3-year survival rate was 66.6% (SE, 10.5) and 63.0% (SE, 9.9), respectively, for patients treated with definitive RT and surgery without adjuvant therapy and was 82.8% (SE, 2.2), 84.9% (SE, 6.5), and 87.8% (SE, 2.8), respectively, for those treated with definitive CRT, surgery with adjuvant RT, and surgery with adjuvant CRT.
Stage III
There were 450 patients with stage III disease included in the analysis who were most commonly treated with surgery with CRT (23.8%) or definitive CRT (67.3%) ( Table 1 ). Patient T classification was associated with the received treatment combination (P<.001), with 64.3% of patients with T1 lesions treated with surgery with or without adjuvant therapy compared with 42.6% of patients with T2 lesions, 47.1% of patients with T3 lesions, and 23.5% of patients with T4 lesions. Neck dissection was performed in 90.0%, 73.7%, and 39.6%, respectively, of patients who received surgery alone, surgery with RT, and surgery with CRT. The median RT dose for those undergoing adjuvant CRT, adjuvant RT, definitive RT, and definitive CRT was 70.0 Gy, 60.0 Gy, 70.0 Gy, and 70.0 Gy, respectively. The 3-year survival rate for the overall group was 75.0% (SE, 2.4).
Survival varied significantly by treatment combination (Table 2) . Treatment with surgery and CRT was associated with improved survival compared with CRT alone (HR, 0.518; 95% CI, 0.292-0.919). Survival curves for this group demonstrated improved survival for patients treated with triple-modality therapy compared with those treated with definitive CRT (Fig, 3C) . The 3-year survival rates were 71.9% (SE, 3.1) and 84.9% (SE, 4.1), respectively, for patients treated with definitive CRT and surgery with adjuvant CRT.
DISCUSSION
As patients with HPV1 cancers increase in frequency to comprise the majority of cases of oropharyngeal cancer (they currently comprise approximately two-thirds of such cancers 6 ), the fundamental treatment and classification paradigms surrounding malignancies of this site are under flux. Several studies have suggested variant staging systems for these cancers and the AJCC has responded with modified criteria for HPV1 oropharynx cancers in the new eighth edition staging atlas. [31] [32] [33] In addition, primary surgical resection, especially with newer surgical approaches such as transoral robotic surgery, which has been shown to safely reduce morbidity after treatment for oropharyngeal carcinomas, has gained favor among providers. [34] [35] [36] [37] Overall, efforts are being made to explore the safe deintensification of treatment among patients with HPV1 oropharyngeal cancer given its more favorable prognosis compared with traditional HPV-disease. 6, [8] [9] [10] [11] [12] [13] [14] 16 In the current study, we outlined whether the number of used treatment modalities could be safely deescalated according to new AJCC eighth edition staging criteria.
Patients with AJCC eighth edition stage I disease currently are recommended to undergo definitive RT or primary surgical resection for T1-2/N0 disease and either definitive CRT or surgery with adjuvant therapy for more advanced disease. 15 For patients with T1-2/N0 tumors, the primary management principle is the use of a single modality to minimize the sequelae associated with treatment-induced toxicity. 38 With the inclusion of what was formerly defined as T1-2/N1-2b disease into the new stage I AJCC eighth edition criteria, as well as the increasing push toward treatment deintensification for this group, the question arises as to whether this treatment paradigm will soon be adopted across AJCC eighth edition stage I disease. It has been reported that the treatment of these patients with CRT or RT alone results in similar outcomes in a single-institution setting. 28 Conversely, the data from the current study suggest that this approach may lead to significant deteriorations in longterm outcomes for these patients, with the results herein demonstrating a >10% worsening of 3-year survival in patients treated with RT alone compared with other treatment modalities. In addition, the current study results suggest that increased use of adjuvant therapies in this subgroup, despite likely worsening treatment-related toxicities, may help to further improve outcomes.
The present treatment standard for patients with AJCC eighth edition stage II disease is definitive CRT or surgery with adjuvant treatment. Both the de-escalation of radiation dose and the omission of chemotherapy from definitive or adjuvant treatment are being studied for patients included in this disease stage. 16 However, given the greatly reduced survival associated with treatment with any single-modality therapy, either RT alone or surgery alone, the current study data suggest that it may not be a safe form of treatment deintensification. Similar to our findings for patients with stage I disease, we found that the addition of adjuvant CRT to definitive surgery was associated with improved outcomes, with a similar albeit nonsignificant trend noted for adjuvant RT.
Patients with AJCC eighth edition N3 and/or T4 (stage III) disease represent the most advanced cases in the current study. The NCCN currently suggests that these patients be treated with definitive CRT or surgery with adjuvant therapy. 15 This group has not been a focus of treatment deintensification and this was reflected in the limited number of patients treated without either definitive or adjuvant CRT in the current study. Notably, we found that treatment with triple-modality therapy was associated with improved survival compared with definitive CRT without surgical resection. This is similar to the findings by Roden et al 29 demonstrating that triplemodality therapy is associated with improved survival for advanced cases of oropharynx cancer with the caveat that although the previous study did not account for HPV status, we included only HPV1 cases in the current study sample. Given the significant differences between HPVand HPV1 disease of the oropharynx, this is an important distinction. It also should be noted that patients in this group had much lower overall survival than low-risk and intermediate-risk patients and represent an important at-risk group within the overall population of HPV1 oropharyngeal cancers, which generally have a good prognosis. These data suggest that treatment intensification to triple-modality therapy, rather than deintensification, may result in improved outcomes in this group. Because it was used nearly one-third as much as definitive CRT, this shift in treatment practice may improve outcomes for a substantial number of patients.
To date, the selection of patients with HPV1 squamous cell carcinoma of the head and neck for deintensification has been based largely on staging criteria. In addition, many trials have included smoking history as a risk stratifier because it is associated with worse outcome. 8 Smoking history was not included in the current data set and further study will be needed to determine whether its inclusion may allow for the more appropriate selection of patients for de-escalation of therapy. Recently, molecular markers associated with outcome in HPV1 tumors were described using data from The Cancer Genome Atlas. Mutations of TRAF3 and CYLD were found to correlate with improved survival and with the absence of HPV genome integration. 39 As with smoking history, additional studies will be needed to determine whether these molecular markers may help to better select patients for de-escalation of therapy.
It was interesting to note that several patients treated surgically did not receive management of possible lymphatic disease with neck dissection. Although this number was smaller among patients with stage II or stage III disease, it still represented a significant percentage of patients who did not receive standard therapy according to NCCN guidelines. 40 Although the receipt of care that is nonconcordant with national treatment guidelines has been reported for other malignancies, [41] [42] [43] this nonguideline therapy may adversely affect patient outcomes. In addition, this may affect the conclusions that can be drawn from the current study with regard to treatment with surgery alone compared with other treatment combinations because a small but significant number of these patients did not receive adequate neck management. It also should be noted that not all tumors are amenable to all forms of therapy. In particular, surgery is more commonly used for lesions of a smaller size, as we found across the 3 risk groups in the current analysis.
As with any study of cancer treatment using registry data, the results of the current study are limited by potential selection bias. Although we were able to control for some of the key variables that influence treatment decision making, including patient comorbidity status as well as disease stage, there are several factors that may influence the used treatment combination for which we did not have the appropriate data with which to control our analysis. The expertise and availability of different therapeutic
Original Article options at the treating institution may guide the chosen treatment combination. Furthermore, interdisciplinary care teams may make assessments of a patient's potential response to different treatment modalities based on molecular information or comorbidities not captured in the Charlson/Deyo Comorbidity Score. Finally, patient preference itself can have an impact on the chosen treatment combination.
In addition, we were limited by the availability of certain data points, including the type of chemotherapy agent used, molecular information such as p16, and patient smoking/alcohol use, which would have allowed for additional controls in the current study. Perhaps the most important missing data point is patient smoking status. Although smoking is more often associated with HPV-oropharynx cancer, it also has been shown to be one of the strongest predictors of survival for patients with HPV1 malignancies. 44 Access to this information would have provided a key additional control as it may be an important variable for the stratification of patient outcomes after de-escalated treatment combinations. Lack of specific chemotherapeutic agent data also is limiting given the particular benefit of cisplatin for this disease. 45 Finally, although HPV testing can be quite accurate, its accuracy can vary by the used diagnostic test. 46 This highlights the importance of the testing laboratory and its experience with this form of diagnostic testing. Although the current study data originate from Commission on Cancer-accredited institutions, it is possible that some of these institutions provide more accurate testing than others. However, given the high survival rates in the current study population, it is unlikely that a significant percentage of them had HPV-disease.
To our knowledge, the current study is the first to investigate the efficacy of treatment deintensification for patients with HPV1 oropharyngeal cancer in a large data series. The size of the current study is a significant strength, one that allowed us to study treatment combinations that are not commonly used for these cancers in conjunction with standard treatment modalities. We believe that these data provide an important cautionary note for future studies of reduced-modality therapy in patients with HPV1 oropharyngeal cancers.
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